By otakuyassine3@gmail.com 
Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) were up 4.9% during trading on Wednesday . The stock traded as high as $38.01 and last traded at $37.73. Approximately 165,844 shares were traded during trading, a decline of 77% from the average daily volume of 714,705 shares. The stock had previously closed at $35.98.
Analysts Set New Price Targets
A number of equities analysts have weighed in on VERA shares. Guggenheim lifted their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. JPMorgan Chase & Co. lifted their target price on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Scotiabank initiated coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target for the company. Wells Fargo & Company initiated coverage on Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price objective on the stock. Finally, Wedbush increased their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $67.50.
Check Out Our Latest Report on Vera Therapeutics
Vera Therapeutics Stock Performance
The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a fifty day simple moving average of $41.83 and a two-hundred day simple moving average of $40.87. The stock has a market cap of $2.36 billion, a PE ratio of -14.28 and a beta of 1.15.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). Equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.
Insider Buying and Selling at Vera Therapeutics
In other news, CEO Marshall Fordyce sold 17,500 shares of the firm’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the transaction, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at approximately $5,993,989.22. This trade represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 52,500 shares of company stock worth $2,305,625 over the last 90 days. Insiders own 21.70% of the company’s stock.
Institutional Trading of Vera Therapeutics
Institutional investors have recently modified their holdings of the company. First Turn Management LLC increased its stake in Vera Therapeutics by 53.3% in the 3rd quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock worth $14,431,000 after purchasing an additional 113,550 shares in the last quarter. Lord Abbett & CO. LLC increased its stake in shares of Vera Therapeutics by 41.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock worth $18,830,000 after purchasing an additional 124,197 shares during the last quarter. Barclays PLC raised its holdings in Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company’s stock valued at $3,774,000 after buying an additional 41,394 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Vera Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company’s stock worth $15,992,000 after purchasing an additional 10,717 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Vera Therapeutics by 2.1% in the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock worth $44,415,000 after buying an additional 20,223 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Read More
Receive News & Ratings for Vera Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vera Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.